DARE-19 Phase III Collaboration between AstraZeneca, Saint Luke’s Mid America Heart Institute and…
OVERLAND PARK, KS, July 29, 2021 (GLOBE NEWSWIRE) -- The findings of DARE-19, a double-blind, placebo-controlled Phase III trial examining Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19, have been…